secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001619856-23-000116
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences gets FDA IND clearance for CB-012 allogeneic CAR-T in r/r AML
--------------------------------------------------------------------------------

- FDA cleared IND for CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy for relapsed/refractory AML.
- AMpLify Phase 1 trial planned to start patient enrollment by mid-2024; first dose level at 25×10^6 CAR-T cells.
- CB-012 is the first allogeneic CAR-T with both PD-1 checkpoint disruption and B2M–HLA-E immune cloaking.
- CB-012 is Caribou's third off-the-shelf CAR-T therapy to enter clinical development.
- AML has ~20,380 new US cases in 2023; median survival for r/r AML is typically <7 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000116/0001619856-23-000116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000116/crbu-20231018.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer